Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms

Blood

Volumn 122, Issue 6, 2013, Pages 999-1006

  Przychodzen, Bartlomiej ^a   Jerez, Andres ^a   Guinta, Kathryn ^a   Sekeres, Mikkael A ^a   Padgett, Richard ^b   Maciejewski, Jaroslaw P ^a   Makishima, Hideki ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; U2AF1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; BONE MARROW CANCER; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOGENETICS; EXON; GENE; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; LEUKEMOGENESIS; MICROARRAY KIT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; RNA SEQUENCE; RNA SPLICE SITE; RNA SPLICING; SEQUENCE ANALYSIS; SOMATIC MUTATION; U2AF1 GENE; ACUTE GRANULOCYTIC LEUKEMIA; COHORT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HEMATOLOGIC DISEASE; MALE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE;

ALTERNATIVE SPLICING; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION, MISSENSE; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NUCLEAR PROTEINS; RIBONUCLEOPROTEINS;

EID: 84886905271     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-480970     Document Type: Article

References (37)

1. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136(4):701-718.
2. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8(10):749-761.
3. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011; 44(1):53-57.
4. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203-3210.
5. Abu Kar S, Jankowska AM, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 2013;98(1):107-113.
6. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120(15):3080-3088.
7. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
8. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
9. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47-52.
10. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012; 119(15):3578-3584.
11. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011;26(3):542-545.
12. Papaemmanuil E, Cazzola M, Boultwood J, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): 1384-1395.
13. Malcovati L, Papaemmanuil E, Bowen DT, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246.
14. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26): 6904-6908.
15. Schnittger S, Meggendorfer M, Kohlmann A, et al. SRSF2 is mutated in 47.2% (77/163) of chronic myelomonocytic leukemia (CMML) and prognostically favorable in cases with concomitant RUNX1 mutations. Blood. 2011;118(21):274. [ASH Annual Meeting Abstracts].
16. Fu Y, Masuda A, Ito M, et al. AG-dependent 39-splice sites are predisposed to aberrant splicing due to a mutation at the first nucleotide of an exon. Nucleic Acids Res. 2011;39(10): 4396-4404.
17. Dunbar AJ, Gondek LP, O’Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349-10357.
18. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood. 2009; 113(25):6403-6410.
19. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21): e198-e206.
20. Tarazona S, García-Alcalde F, Dopazo J, et al. Differential expression in RNA-seq: a matter of depth. Genome Res. 2011;21(12):2213-2223.
21. Wu J, Akerman M, Sun S, et al. SpliceTrap: a method to quantify alternative splicing under single cellular conditions. Bioinformatics. 2011; 27(21):3010-3016.
22. Crooks GE, Hon G, Chandonia JM, et al. WebLogo: a sequence logo generator. Genome Res. 2004;14(6):1188-1190.
23. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18(20):6097-6100.
24. Maciejewski JP, Tiu RV, O’Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol. 2009;146(5):479-488.
25. Gondek LP, Tiu R, O’Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3): 1534-1542.
26. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65(14):6071-6079.
27. Tiu RV, Gondek LP, O’Keefe CL, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol. 2009;27(31):5219-5226.
28. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat. 2007;1(1): 107-129.
29. Pan YR, Lee EY. UV-dependent interaction between Cep164 and XPA mediates localization of Cep164 at sites of DNA damage and UV sensitivity. Cell Cycle. 2009;8(4):655-664.
30. Sivasubramaniam S, Sun X, Pan YR, Wang S, Lee EY. Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1. Genes Dev. 2008;22(5):587-600.
31. Schmid N, Zagrovic B, van Gunsteren WF. Mechanism and thermodynamics of binding of the polypyrimidine tract binding protein to RNA. Biochemistry. 2007;46(22):6500-6512.
32. Oberstrass FC, Auweter SD, Erat M, et al. Structure of PTB bound to RNA: specific binding and implications for splicing regulation. Science. 2005;309(5743):2054-2057.
33. Conte MR, Grüne T, Ghuman J, et al. Structure of tandem RNA recognition motifs from polypyrimidine tract binding protein reveals novel features of the RRM fold. EMBO J. 2000;19(12):3132-3141.
34. Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 2011;1(2):137-143.
35. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
36. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399): 502-506.
37. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-1160.